LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19, Flu and RSV Combination Test to Increase Testing Capacity and Speed Time to Diagnosis

By LabMedica International staff writers
Posted on 01 Jul 2022
Print article
Image: BD MAX molecular diagnostic respiratory viral panel is CE marked to IVD directive (Photo courtesy of BD)
Image: BD MAX molecular diagnostic respiratory viral panel is CE marked to IVD directive (Photo courtesy of BD)

A new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) can help eliminate the need for multiple tests or doctor visits and aid clinicians in implementing the right treatment plan quickly. The co-testing approach can also help to increase testing capacity during the busy flu season and speed the time to diagnosis.

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has launched the BD MAX Respiratory Viral Panel (RVP) which uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. The BD MAX RVP assay is an RT- PCR assay that detects and differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in approximately two hours, with the easy-to-use and automated workflow of the BD MAX System. The BD MAX System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period.

The BD RVP assay for BD MAX System is an important addition to the extensive number of assays available on the system across respiratory, STI, gastrointestinal, women's health and health care associated infections. The broad menu of assays in combination with the open system capabilities on a fully automated sample-to-result molecular platform make the BD MAX System a valued platform for infectious disease testing in thousands of labs worldwide. BD MAX RVP is currently available in countries that recognize the CE mark. BD plans to submit for Emergency Use Authorization from the U.S. Food and Drug Administration in the coming weeks.

"SARS-Cov-2, influenza and RSV are a triple threat, as patient symptoms and clinical presentation can be nearly identical," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD. "A combined testing panel is key to enabling clinicians to quickly and efficiently diagnose, differentiate and treat patients to help manage the spread of the infections."

Related Links:
BD 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more